Does Rallies show 13F holders for AIM?

Yes. Rallies tracks hedge fund and 13F ownership data for AIM, including fund names, share counts, latest tracked quarter, and position changes when available.

Is AIM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AIM. It does not provide personalized investment advice.

AIM (AIM ImmunoTech Inc.) Stock Analysis - Hedge Fund Holdings

AIM ImmunoTech Inc. (AIM) is a publicly traded Healthcare sector company. As of May 21, 2026, AIM trades at $0.26 with a market cap of $6.36M and a P/E ratio of -0.05. AIM moved -38.69% today. Year to date, AIM is -80.10%; over the trailing twelve months it is +102.64%. Its 52-week range spans $0.06 to $20.33. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces AIM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns AIM stock?

Hedge funds tracked by Rallies that own AIM include Citadel Advisors, Renaissance Technologies, and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for AIM ImmunoTech Inc..

AIM Key Metrics

Key financial metrics for AIM
Metric	Value
Price	$0.26
Market Cap	$6.36M
P/E Ratio	-0.05
EPS	$-8.62
Dividend Yield	0.00%
52-Week High	$20.33
52-Week Low	$0.06
Volume	11.72M
Avg Volume	0
Revenue (TTM)	$88.00K
Net Income	$-13.96M
Gross Margin	0.00%

Top Hedge Funds Holding AIM

Citadel Advisors holds 358.99K shares of AIM, changed -21.58% as of Dec 31, 2024.
Renaissance Technologies holds 260.48K shares of AIM, changed +7.10% as of Dec 31, 2024.
Two Sigma holds 71.31K shares of AIM, changed -42.96% as of Dec 31, 2024.

Latest AIM News

AIM ImmunoTech Raises $2.4 Million via 7.52 M Shares and 15 M Series I Warrants — May 20, 2026
AIM ImmunoTech Shows 50% ORR, 21% Complete Responses in Phase 2 Ovarian Cancer Trial — May 7, 2026
AIM ImmunoTech Plans Phase 3 Pancreatic Cancer Trial After Over 100-Patient Phase 2 Success — Apr 16, 2026
AIM ImmunoTech Flags Going Concern, Cites Positive Phase 2 Pancreatic Cancer Data — Apr 13, 2026
Directa Plus warns of administration risk without £2.5m funding; Greatland grows Telfer to 8Moz; 88 Energy targets 64m barrels — Mar 30, 2026

Recent AIM Insider Trades

Equels Thomas K bought 107 (~$823.579) on Jun 13, 2025.
Equels Thomas K bought 103 (~$896.1) on Jun 12, 2025.
MITCHELL WILLIAM M bought 196.85K (~$5.00K) on Apr 11, 2025.

AIM Analyst Consensus

1 analysts cover AIM: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.00.

Common questions about AIM

Who owns AIM stock?: Hedge funds tracked by Rallies that own AIM include Citadel Advisors, Renaissance Technologies, and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for AIM ImmunoTech Inc..
Does Rallies show 13F holders for AIM?: Yes. Rallies tracks hedge fund and 13F ownership data for AIM, including fund names, share counts, latest tracked quarter, and position changes when available.
Is AIM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AIM. It does not provide personalized investment advice.